Control mice received an equivalent volume of saline solution
Analytical-method literature can explain why orthogonal methods are useful, but it does not verify a specific supplier lot
Figure 2 represents the pathophysiology of an altered IGF-1/GH/insulin axis, and potential beneficial actions of IGF-1 therapy

WATER, ETHYLHEXYL METHOXYCINNAMATE, BUTYLENE GLYCOL, ETHYLHEXYL SALICYLATE, OCTOCRYLENE, BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE, BUTYL METHOXYDIBENZOYLMETHANE, DIPROPYLENE GLYCOL, NIACINAMIDE, SQUALANE, C14-22 ALCOHOLS, 1,2-HEXANEDIOL, POLYGLYCERYL-2 STEARATE, PROPANEDIOL, HYDROXYACETOPHENONE, GLYCERYL STEARATE, STEARYL ALCOHOL, C12-20 ALKYL GLUCOSIDE, TROMETHAMINE, CENTELLA ASIATICA EXTRACT, CARBOMER, MELALEUCA ALTERNIFOLIA (TEA TREE) EXTRACT, HIPPOPHAE RHAMNOIDES FRUIT EXTRACT, VITIS VINIFERA (GRAPE) FRUIT EXTRACT, ACRYLATES/C10-30 ALKYL ACRYLATE CROSSPOLYMER, UNCARIA SINENSIS EXTRACT, GLYCERIN, ADENOSINE, DISODIUM EDTA, ORYZA SATIVA (RICE) BRAN EXTRACT, HYDROGENATED PHOSPHATIDYLCHOLINE, CAPRYLIC/CAPRIC TRIGLYCERIDE, SODIUM HYALURONATE, GLUCOSE, HYDROLYZED COLLAGEN, SUCROSE STEARATE, GLUTATHIONE, CYCLODEXTRIN, CETEARYL ALCOHOL, CAPRYLYL GLYCOL, BETA-GLUCAN, CAPRYLHYDROXAMIC ACID, ETHYLHEXYLGLYCERIN, ASIATIC ACID, ASIATICOSIDE, MADECASSIC ACID, MADECASSOSIDE, TROPOLONE, HYALURONIC ACID, POTASSIUM HYALURONATE *** Ingredients are subject to change at the manufacturer's discretion

Oral bioavailability has not been clearly measured in humans